MENU
Aim higher

NOVA-CARE

A novel therapeutic antibody and companion diagnostic for non-ischaemic cardiac remodelling

NOVA-CARE aims to establish preclinical efficacy in mouse and porcine disease models for a novel therapeutic monoclonal antibody (mAb) to prevent non-ischaemic heart failure (NI-HF) by targeting EDA-fibronectin (EDA). This protein is upregulated during adverse cardiac remodelling, which leads to heart failure (HF). In addition, a companion diagnostic will be developed using biomarkers linked to EDA expression, to identify patients at risk for developing NI-HF, and to optimize mAb treatment.
Acronym: 
NOVA-CARE
Project ID: 
10 421
Ranking: 
21
Cut-off: 
5
Start date: 
01-10-2016
Project Duration: 
36months
Project costs: 
2 231 120.00€
Technological Area: 
Heart and blood circulation illnesses
Market Area: 
Therapeutic